BWXT's $800M Sale: A Nuclear Pivot and a Bet on Radiopharmaceuticals

LYNCHBURG, VA – August 03, 2026

In a move that signals a major strategic realignment, nuclear technology leader BWX Technologies, Inc. (NYSE: BWXT) announced it will sell its rapidly growing medical business to Nordic Capital, a private equity firm with deep roots in healthcare investment. The transaction, valued at up to $800 million, will see BWXT Medical and its associated stable medical isotopes business transition to new ownership, while allowing BWXT to retain a significant minority stake.

This landmark deal is more than a simple acquisition; it represents a calculated pivot for both entities. For BWXT, it is a strategic divestment designed to sharpen its focus and channel capital into its foundational nuclear security and energy markets. For Nordic Capital, it is a substantial bet on the future of nuclear medicine, leveraging its expertise to scale a promising player in the burgeoning radiopharmaceutical sector. The transaction, subject to customary regulatory approvals, is expected to close by the end of 2026.

A Strategic Pivot to the Nuclear Core

BWXT's decision to divest its medical unit comes at a time of significant strength for the division. Since acquiring the business in 2018, the company has successfully tripled its revenue and expanded its portfolio to include novel therapeutic isotopes. However, this success has also highlighted its position as a non-core asset within a company increasingly dedicated to national security and commercial nuclear power.

"As the business enters its next phase, this transaction provides an opportunity for the medical team to grow under an owner deeply committed to the healthcare sector, as we concentrate management resources and capital on our core businesses in nuclear national security and nuclear power," said Rex D. Geveden, BWXT president and chief executive officer, in a statement. The move is a clear execution of a long-term strategy to streamline operations and double down on its primary markets.

This strategic refocus is not happening in a vacuum. The capital injection from the sale follows other aggressive moves by BWXT to fortify its core operations. Just last month, the company acquired Precision Components Group for $200 million, significantly expanding its U.S.-based nuclear manufacturing capacity. This focus is reflected in its financial performance, with a reported backlog of $8.4 billion driven by multi-year awards in its government and commercial nuclear segments. By divesting the medical unit, BWXT can deploy the nearly billion-dollar proceeds to further accelerate growth and innovation in these high-stakes arenas, from naval propulsion systems to next-generation nuclear reactors.

Nordic Capital's Big Bet on Nuclear Medicine

For Nordic Capital, the acquisition of BWXT Medical is a strategic addition to a carefully curated healthcare portfolio. The firm has deployed over €11 billion in the sector and has a proven track record of identifying and scaling high-potential life sciences and pharmaceutical companies. This deal fits squarely within its investment thesis, targeting the critical intersection of pharmaceuticals and advanced medical technology.

"Nordic Capital has a long track record of successful investments across both pharmaceuticals and life sciences, and radiopharmaceuticals sit squarely at the intersection of the two," noted Christian Hedegaard, a partner at Nordic Capital Advisors. He emphasized the firm's conviction in the BWXT Medical team and the "significant potential to scale the business and expand access to cutting-edge radiopharmaceutical therapy."

This isn't Nordic Capital's first foray into the space. Its 2025 partnership with Minerva Imaging, a specialized radiopharmaceutical research and manufacturing organization, signaled a clear ambition to build a global leader in targeted radionuclide therapies. The acquisition of BWXT Medical, with its established manufacturing capabilities and product portfolio, represents a major step toward realizing that goal. The plan is to inject capital and operational expertise to expand production, accelerate the development of new treatments, and solidify the company's market position.

Fueling Growth in a Booming Market

The timing of Nordic Capital’s investment is critical, as the global radiopharmaceutical market is on a steep growth trajectory. Valued at approximately $7.5 billion in 2026, the market is projected to nearly double to over $13.6 billion by 2030, driven by a convergence of powerful trends. The rise of precision oncology and "theranostics"—an approach that combines diagnostic imaging with targeted therapy—is creating unprecedented demand for novel isotopes.

These advanced treatments offer a more personalized and effective way to fight complex diseases, particularly cancer. With a growing and aging global population leading to a higher incidence of chronic illness, the need for such innovative diagnostic and therapeutic tools has never been greater. Technological advancements, including the use of artificial intelligence in drug design and imaging analysis, are further accelerating the pace of innovation. While the industry faces challenges, including complex supply chains and stringent regulatory hurdles, the overwhelming momentum is toward growth, making it a highly attractive field for specialized investors.

Deconstructing the Deal: A Hybrid Partnership for the Future

The structure of the transaction reveals a nuanced, forward-looking strategy. The "up to $800 million" valuation suggests that a portion of the final price is likely tied to performance-based milestones, aligning the interests of both parties toward the future success of the medical business. More telling is BWXT's decision to retain a minority ownership stake.

This is not a clean break. By remaining a partner, BWXT ensures it will benefit from the anticipated growth it helped seed, validating its bullish outlook on the radiopharmaceutical market. The arrangement also creates a powerful synergy: the new, independent medical company gains the agility and focused investment of a private equity owner while retaining access to the deep institutional knowledge of its former parent. According to the agreement, BWXT will continue to provide specialized isotope and radiochemical expertise, ensuring a smooth transition and ongoing collaboration.

This hybrid ownership model creates a new entity poised to navigate the complexities of the nuclear medicine landscape with a unique combination of financial backing, operational focus, and technical expertise, potentially accelerating the journey of next-generation therapies from the lab to the clinic.